Articles with public access mandates - Giuseppe SaglioLearn more
Not available anywhere: 6
BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP
A Morotti, C Panuzzo, S Crivellaro, B Pergolizzi, U Familiari, AH Berger, ...
Leukemia 28 (6), 1326-1333, 2014
Mandates: US National Institutes of Health
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia
C Quintarelli, B De Angelis, S Errichiello, S Caruso, N Esposito, I Colavita, ...
Leukemia research 38 (2), 236-242, 2014
Mandates: Government of Italy
Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?
C Fava, G Saglio
Seminars in hematology 47 (4), 319-326, 2010
Mandates: US National Institutes of Health
Point: Is there a best duration of deep molecular response to achieve therapy‐free remission in chronic myeloid leukaemia?
RP Gale, G Saglio
British Journal of Haematology 192 (1), 2021
Mandates: National Institute for Health Research, UK
Inhibition OF USP7 induces selective cancer cell death in chronic lymphocytic leukemia
G Carrà, C Panuzzo, D Torti, G Parvis, S Crivellaro, M Volante, D Morena, ...
Clinical Lymphoma, Myeloma and Leukemia 16, S49-S50, 2016
Mandates: Government of Italy
AML-201: Synthetic Lethality in Acute Myeloid Leukemia: A Focus on Dihydroorotate Dehydrogenase Inhibitors
P Circosta, V Gaidano, M Houshmand, S Sainas, A Pippione, M Giorgis, ...
Clinical Lymphoma Myeloma and Leukemia 20, S190, 2020
Mandates: AIRC Foundation for Cancer Research in Italy
Available somewhere: 93
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A Hochhaus, M Baccarani, RT Silver, C Schiffer, JF Apperley, F Cervantes, ...
Leukemia 34 (4), 966-984, 2020
Mandates: National Institute for Health Research, UK
Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial
JE Cortes, G Saglio, HM Kantarjian, M Baccarani, J Mayer, C Boqué, ...
Journal of Clinical Oncology 34 (20), 2333-2340, 2016
Mandates: US National Institutes of Health
PML targeting eradicates quiescent leukaemia-initiating cells
K Ito, R Bernardi, A Morotti, S Matsuoka, G Saglio, Y Ikeda, J Rosenblatt, ...
Nature 453 (7198), 1072-1078, 2008
Mandates: US National Institutes of Health
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Experts in Chronic Myeloid Leukemia
Blood, The Journal of the American Society of Hematology 121 (22), 4439-4442, 2013
Mandates: US National Institutes of Health
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow …
HM Kantarjian, A Hochhaus, G Saglio, C De Souza, IW Flinn, L Stenke, ...
The lancet oncology 12 (9), 841-851, 2011
Mandates: US National Institutes of Health
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
RA Larson, A Hochhaus, TP Hughes, RE Clark, G Etienne, DW Kim, ...
Leukemia 26 (10), 2197-2203, 2012
Mandates: US National Institutes of Health
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
E Jabbour, HM Kantarjian, G Saglio, JL Steegmann, NP Shah, C Boqué, ...
Blood, The Journal of the American Society of Hematology 123 (4), 494-500, 2014
Mandates: US National Institutes of Health
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
NCP Cross, HE White, D Colomer, H Ehrencrona, L Foroni, E Gottardi, ...
Leukemia 29 (5), 999-1003, 2015
Mandates: European Commission
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
FJ Giles, PD Le Coutre, J Pinilla-Ibarz, RA Larson, N Gattermann, ...
Leukemia 27 (1), 107-112, 2013
Mandates: US National Institutes of Health
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
RJ Kreitman, C Dearden, PL Zinzani, J Delgado, L Karlin, T Robak, ...
Leukemia 32 (8), 1768-1777, 2018
Mandates: US National Institutes of Health
Dasatinib in imatinib‐resistant or‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034
NP Shah, P Rousselot, C Schiffer, D Rea, JE Cortes, J Milone, ...
American journal of hematology 91 (9), 869-874, 2016
Mandates: US National Institutes of Health
Chronic myeloid leukemia stem cells
M Houshmand, G Simonetti, P Circosta, V Gaidano, A Cignetti, ...
Leukemia 33 (7), 1543-1556, 2019
Mandates: National Institute for Health Research, UK
Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 study: efficacy and tolerability of 140 …
G Saglio, A Hochhaus, YT Goh, T Masszi, R Pasquini, F Maloisel, P Erben, ...
Cancer 116 (16), 3852-3861, 2010
Mandates: US National Institutes of Health
Chronic myeloid leukemia: reminiscences and dreams
TI Mughal, JP Radich, MW Deininger, JF Apperley, TP Hughes, ...
Haematologica 101 (5), 541, 2016
Mandates: US National Institutes of Health, National Institute for Health Research, UK
Publication and funding information is determined automatically by a computer program